Christopher T. Breen is a medical student at Yale School of Medicine. He received an A.B. in Politics from Princeton University. David A. Fiellin, M.D., is a Professor of Medicine, Emergency Medicine and Public Health at Yale where he directs the Program in Addiction Medicine. His research is focused on implementing addiction treatment in general medical settings.
J Law Med Ethics. 2018 Jun;46(2):272-278. doi: 10.1177/1073110518782934.
Buprenorphine is a form of opioid agonist treatment that has been demonstrated to be an effective medication for opioid addiction. It is available in different formulations and marketed under various trade names, including commonly as a buprenorphine/naloxone combination. This paper provides an overview of existing literature on the supply of buprenorphine treatment, the ability of people to access treatment with buprenorphine, and the quality of treatment received. We argue that better data for each of these aspects of treatment could inform policy to expand effective treatment with buprenorphine, and we suggest steps to obtain and act on such data.
丁丙诺啡是一种阿片类激动剂治疗方法，已被证明是治疗阿片类药物成瘾的有效药物。它有不同的剂型，并以不同的商品名销售，包括通常作为丁丙诺啡/纳洛酮的组合。本文概述了关于丁丙诺啡治疗供应、人们获得丁丙诺啡治疗的能力以及所接受治疗质量的现有文献。我们认为，更好地了解治疗的这些方面的数据可以为扩大丁丙诺啡有效治疗提供政策依据，我们建议采取措施获取和利用这些数据。
